Both SNX2 and SNX1 mRNA levels were significantly decreased in stage I tumors and remained low at more advanced disease stages (Figure 7b and Supplementary Figure 2), suggesting an early and sustained alteration in CRC pathogenesis. This evidence concerns the gene SNX2 and colorectal carcinoma.